AI Article Synopsis

  • Systemic treatments for moderate-to-severe psoriasis can lead to cutaneous infections, although the specific risks of these infections are not well documented.
  • In a study involving 878 psoriasis patients treated with biologics, the incidence of cutaneous bacterial, viral, and fungal infections was analyzed, revealing low but significant rates for each type.
  • The findings indicated that specific treatments, such as tumor necrosis factor-α and interleukin-17 inhibitors, are linked to higher risks of bacterial and fungal infections, respectively, highlighting the need for careful monitoring by dermatologists.

Article Abstract

Systemic treatments are important for patients with moderate-to-severe psoriasis; however, they may occasionally cause adverse infectious events. Although the risk of severe infections with psoriatic treatments is well established, little is known about cutaneous infections. Therefore, we studied the frequency of cutaneous infections in patients with psoriasis who underwent biologic treatment. A total of 878 patients (237 females and 641 males) were analyzed in this follow-up survey conducted in 2020 and based on the Western Japan Psoriasis Registry. The observed skin phenotypes were psoriasis vulgaris (83.3%), pustular psoriasis (7.5%), and psoriatic arthritis (28.9%). The most frequently prescribed systemic drug was apremilast (11.3%), followed by ixekizumab (11.0%), risankizumab (10.9%), and secukinumab (10.4%). The incidence of cutaneous bacterial infections was 12 (1.37% of the total patients), with cellulitis being the most common (8/12, 67%). The incidence of viral infections was 11 (1.25%) including the most common, herpes zoster (9/11, 82%); and that of fungal infections was 45 (5.13%) including 33 (73%) and seven (16%) patients with trichophytosis and oral candidiasis, respectively. Multivariate analysis revealed that cutaneous bacterial infections were frequently observed in patients receiving tumor necrosis factor-α (odds raio [OR] 9.917, 95% confidence interval [CI] 2.069-47.572, p = 0.004) and interleukin (IL)-17 (OR 10.798, 95% CI 2.35-49.616, p = 0.002) inhibitor treatments. A history of otitis media and treatment with oral medications (OR 4.50, 95% CI 1.281-15.804, p = 0.019 and OR 3.80, 95% CI 1.141-12.679, p = 0.03 respectively) were associated with a higher ORs for cutaneous viral infections. Furthermore, age and use of IL-17 inhibitors were associated with elevated ORs for fungal infections. In conclusion, our study reveals that systemic therapies may increase the risk of cutaneous viral infections. Therefore, dermatologists should exercise caution in this regard.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483952PMC
http://dx.doi.org/10.1111/1346-8138.17245DOI Listing

Publication Analysis

Top Keywords

cutaneous infections
12
viral infections
12
infections
11
risk cutaneous
8
cutaneous bacterial
8
bacterial infections
8
fungal infections
8
cutaneous viral
8
cutaneous
7
psoriasis
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!